GlassScriptPhysician profile
Avtar Sekhon
NPI 1760536528
$6,550.55
in general payments reported to CMS, 2019-2025
46 companies · $1,214 in 2025
The $1,214 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $817 · 2020: $794 · 2021: $958 · 2022: $639 · 2023: $920 · 2024: $1,208 · 2025: $1,214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,341.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,835.52 | 2019-2025 | Ubrelvy, Vraylar, Viberzi |
| Pfizer INC. | $796.88 | 2019-2025 | |
| Lilly USA, LLC | $437.12 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $421.16 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $335.88 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Novo Nordisk INC | $306.55 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Gilead Sciences, INC. | $238.91 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $192.10 | 2022-2024 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $185.50 | 2019-2025 | Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $166.26 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $122.02 | 2019-2021 | |
| Exact Sciences Corporation | $112.11 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $111.63 | 2019-2023 | Otezla, Repatha |
| Abbott Laboratories | $110.41 | 2022-2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $105.81 | 2024 | Voquezna |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avtar Sekhon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.